摘要
Abstract
Objective:To review the therapeutical effect of trimetazidine and shexiang baoxin pill on chronic heart failure. Methods:The literature of randomized and controlled trialls(RCT) about treatment of chronic heart failure with trimetazidine and shexiang baoxin pill were retrieved from Cochrane Library,ProQuest Research Library,MEDLINE,Embase,PEDro,OpenSIGLE,NTIS, ScienceDirect,CNKI,VIP,Wanfang Data and CBM(by Apr 30,2013),and then 2 reviewers inde-pendently chose RCT,extracted materials,checked crossly and gave methodological quality evalua-tion. Meta analysis was conducted by using Revman 5.2 software. Results:A total of 6 trials and 387 patients were discovered. Meta analysis showed that at the end of the study,compared with routine remedy alone,the remedy of trimetazidine and shexiang baoxin pill on chronic heart failure obtained abvious amelioration on left ventricular ejection fraction(LVEF),left ventricular end diastolic diam-eter(LVEDD),left ventricular end shrink diameter(LVESD)and the walking distance of 6 min-utes,WMD(95%CI):5.99(5.90 to 6.08),-5.04(-5.90 to-4.19),-4.6(-8.59 to-0.64),42.73 (32.48 to 52.97). There were not obvious adverse reactions. Conclusion:The existing evidence shows that the therapy of trimetazidine and shexiang baoxin pill is effective to chronic heart failure and can ameliorate left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter (LVEDD),left ventricular end shrink diameter(LVESD)and the walking distance of 6 minutes. As the limitation of the quality of enclosed literature,the review on the curative effect of chronic heart failure expects more randomized controlled double-blind trials with high quality.关键词
曲美他嗪/麝香保心丸/慢性心力衰竭/系统评价Key words
trimetazidine/shexiang baoxin pill/chronic heart failure/systemic evaluation分类
医药卫生
